A prospective, observational study evaluating switching to Insulin Glargine 300 U/mL (Gla -300) after failure of basal supported oral therapy with other basal insulins in type II diabetes patients in daily clinical practice

Trial Profile

A prospective, observational study evaluating switching to Insulin Glargine 300 U/mL (Gla -300) after failure of basal supported oral therapy with other basal insulins in type II diabetes patients in daily clinical practice

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Insulin glargine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms TOP-2
  • Most Recent Events

    • 22 Jul 2017 New trial record
    • 13 Jun 2017 Interim results (n=661) presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top